Zevra Therapeutics Inc - ZVRA Enterprise Value-to-Sales Ratio

Public company logo of Zevra Therapeutics Inc (ZVRA)

Zevra Therapeutics (ZVRA) is creating a comprehensive environment for combating rare pathologies by integrating science and patient care. The EV/Sales market multiple reflects valuation dynamics, where 2337.30 determines the current status of the parameter. While geopolitical disruptions in raw material supplies create risks, patent control and a lack of neurological analogs ensure high margins for the company.

Zevra Therapeutics Inc (ZVRA): Company Value to Revenue from 11/23/2025 to 11/20/2026

Financial and market metric breakdowns for Kempharm (ZVRA)

- money and cash flow information:
Initial company analysis:Zevra Therapeutics ZVRA
Core merchandise of Zevra Therapeutics Inc

This indicator determines the market value of the business, including net debt, relative to annual sales volume. The ratio allows for the valuation of a single dollar of revenue without distortions caused by debt load. By analyzing the firm's valuation via the EV/Sales multiple, an investor identifies the limits of overpaying for an asset. For Zevra Therapeutics (ZVRA), this metric reflects the capitalization of potential within the orphan drug niche. Stable production outsourcing and digital transformation make this indicator a key measure of business scaling efficiency.